INTRODUCTION: PLS is defined as pure upper motor neuron disease/dysfunction (PUMND) beyond 48 months after symptom onset. We know little about its early stages, but such knowledge would help to identify the mechanisms underlying PLS and ALS and determine why PLS patients seem to be protected against lower MND (LMND). METHODS: We reviewed 622 MND cases during a 4-year period and identified 34 patients with PUMND (5.4%). RESULTS: Among 23 cases with follow-up data/electromyograms (EMGs; 2 had only 1 EMG), 13 (57%) remained classified as PUMND, and 8 (35%) developed LMND (mean, 51.4 months after onset). Of these 8, LMND developed in 3 after 48 months from symptom onset. Patients with PUMND and LMND were more functionally impaired (P = 0.02). Separately, we identified 5 patients with PUMND who developed LMND long after 48 months (range, 50-127 months). CONCLUSIONS: PLS belongs to the ALS spectrum, and perhaps all cases eventually develop LMND.
INTRODUCTION:PLS is defined as pure upper motor neuron disease/dysfunction (PUMND) beyond 48 months after symptom onset. We know little about its early stages, but such knowledge would help to identify the mechanisms underlying PLS and ALS and determine why PLSpatients seem to be protected against lower MND (LMND). METHODS: We reviewed 622 MND cases during a 4-year period and identified 34 patients with PUMND (5.4%). RESULTS: Among 23 cases with follow-up data/electromyograms (EMGs; 2 had only 1 EMG), 13 (57%) remained classified as PUMND, and 8 (35%) developed LMND (mean, 51.4 months after onset). Of these 8, LMND developed in 3 after 48 months from symptom onset. Patients with PUMND and LMND were more functionally impaired (P = 0.02). Separately, we identified 5 patients with PUMND who developed LMND long after 48 months (range, 50-127 months). CONCLUSIONS:PLS belongs to the ALS spectrum, and perhaps all cases eventually develop LMND.
Authors: N Le Forestier; T Maisonobe; A Piquard; S Rivaud; L Crevier-Buchman; F Salachas; P F Pradat; L Lacomblez; V Meininger Journal: Brain Date: 2001-10 Impact factor: 13.501
Authors: Mike A Singer; Suleiman Kojan; Richard J Barohn; Laura Herbelin; Sharon P Nations; Jaya R Trivedi; Carlayne E Jackson; Dennis K Burns; Philip J Boyer; Gil I Wolfe Journal: J Clin Neuromuscul Dis Date: 2005-09
Authors: Mamede de Carvalho; Reinhard Dengler; Andrew Eisen; John D England; Ryuji Kaji; Jun Kimura; Kerry Mills; Hiroshi Mitsumoto; Hiroyuki Nodera; Jeremy Shefner; Michael Swash Journal: Clin Neurophysiol Date: 2007-12-27 Impact factor: 3.708
Authors: Andy J Liu; Jessica E Chang; Georges Naasan; Adam L Boxer; Bruce L Miller; Salvatore Spina Journal: Neurocase Date: 2020-02-23 Impact factor: 0.881
Authors: Martin R Turner; Richard J Barohn; Philippe Corcia; John K Fink; Matthew B Harms; Matthew C Kiernan; John Ravits; Vincenzo Silani; Zachary Simmons; Jeffrey Statland; Leonard H van den Berg; Hiroshi Mitsumoto Journal: J Neurol Neurosurg Psychiatry Date: 2020-02-06 Impact factor: 10.154
Authors: Luis De-Bernardi-Ojuel; Laura Torres-Collado; Manuela García-de-la-Hera Journal: Int J Environ Res Public Health Date: 2021-02-03 Impact factor: 3.390
Authors: Hiroshi Mitsumoto; Peter L Nagy; Chris Gennings; Jennifer Murphy; Howard Andrews; Raymond Goetz; Mary Kay Floeter; Jonathan Hupf; Jessica Singleton; Richard J Barohn; Sharon Nations; Christen Shoesmith; Edward Kasarskis; Pam Factor-Litvak Journal: Neurol Genet Date: 2015-04-14
Authors: Alma Osmanovic; Isabel Gogol; Helge Martens; Maylin Widjaja; Kathrin Müller; Olivia Schreiber-Katz; Friedrich Feuerhake; Claus-Dieter Langhans; Gunnar Schmidt; Peter M Andersen; Albert C Ludolph; Jochen H Weishaupt; Frank Brand; Susanne Petri; Ruthild G Weber Journal: Genes (Basel) Date: 2021-12-29 Impact factor: 4.096